New research: The PI3K/AKT Pathway Inhibitor ISC-4 Induces Apoptosis and Inhibits Growth of Leukemia in Preclinical Models of Acute Myeloid Leukemia: Acute myeloid leukemia is a heterogeneous disease with a 5-year survival rate of 28.3%, and… https://t.co/
New article: The PI3K/AKT Pathway Inhibitor ISC-4 Induces Apoptosis and Inhibits Growth of Leukemia in Preclinical Models of Acute Myeloid Leukemia. https://t.co/4LQWu2zya2 #AML #leusm #hematology
The PI3K/AKT Pathway Inhibitor ISC-4 Induces Apoptosis and Inhibits Growth of Leukemia in Preclinical Models of Acute Myeloid Leukemia. https://t.co/SwlUxFOMQF
Our latest publication @FrontOncology Targeting the PI3K/AKT pathway with a novel compound, ISC-4 for the treatment of Acute Myeloid Leukemia. #CancerResearch @FrontiersIn #ABIMresearch #medtwitter https://t.co/Ahs2BF7VH0 https://t.co/zDb164tqqE